scholarly journals One-time intrathecal triamcinolone acetonide application alters the redox potential in cerebrospinal fluid of progressive multiple sclerosis patients: a pilot study

2016 ◽  
Vol 9 (4) ◽  
pp. 264-268 ◽  
Author(s):  
Thomas Müller ◽  
Thomas Herrling ◽  
Sven Lütge ◽  
Lutz Lohse ◽  
Gabi Öhm ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cerebrospinal Fluid ◽  
Pilot Study ◽  
Redox Potential ◽  
Triamcinolone Acetonide ◽  
Progressive Multiple Sclerosis ◽  
Multiple Sclerosis Patients

Efficacy and safety of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients

2003 ◽  
Vol 211 (1-2) ◽  
pp. 81-84 ◽  
Author(s):  
Volker Hoffmann ◽  
Sebastian Schimrigk ◽  
Saida Islamova ◽  
Kerstin Hellwig ◽  
Carsten Lukas ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Triamcinolone Acetonide ◽  
Progressive Multiple Sclerosis ◽  
Efficacy And Safety ◽  
Multiple Sclerosis Patients

scholarly journals Contactin-1 and contactin-2 in cerebrospinal fluid as potential biomarkers for axonal domain dysfunction in multiple sclerosis

2018 ◽  
Vol 4 (4) ◽  
pp. 205521731881953 ◽  
Author(s):  
Madhurima Chatterjee ◽  
Marleen JA Koel-Simmelink ◽  
Inge MW Verberk ◽  
Joep Killestein ◽  
Hugo Vrenken ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Multiple Sclerosis ◽  
Cerebrospinal Fluid ◽  
Progressive Multiple Sclerosis ◽  
Clinically Isolated Syndrome ◽  
Resonance Imaging ◽  
Secondary Progressive ◽  
Relapsing Remitting ◽  
Multiple Sclerosis Patients ◽  
Relapsing Remitting Multiple Sclerosis

Background Contactin-1 and contactin-2 are important for the maintenance of axonal integrity. Objective To investigate the cerebrospinal fluid levels of contactin-1 and contactin-2 in multiple sclerosis patients and controls, and their potential use as prognostic markers for neurodegeneration. Methods Cerebrospinal fluid contactin-1 and contactin-2 were measured in relapsing–remitting multiple sclerosis ( n = 41), secondary progressive multiple sclerosis ( n = 26) and primary progressive multiple sclerosis patients ( n = 13) and controls ( n = 18), and in a second cohort with clinically isolated syndrome patients ( n = 88, median clinical follow-up period of 2.3 years) and controls ( n = 20). Correlations/linear regressions were analysed with other baseline cerebrospinal fluid axonal damage markers and cross-sectional/longitudinal magnetic resonance imaging features. Results Contactin-1 and contactin-2 levels were up to 1.4-fold reduced in relapsing–remitting multiple sclerosis (contactin-1: p = 0.01, contactin-2: p = 0.02) and secondary progressive multiple sclerosis (contactin-1: p = 0.05, contactin-2: p = 0.02) compared to controls. In clinically isolated syndrome patients, contactin-1 tended to increase when compared to controls ( p = 0.07). Both contactin-1 and contactin-2 correlated with neurofilament light, neurofilament heavy and magnetic resonance imaging metrics differently depending on the disease stage. In clinically isolated syndrome patients, baseline contactin-2 level (β = –0.42, p = 0.04) predicted the longitudinal decline in cortex volume. Conclusion Cerebrospinal fluid contactin-1 and contactin-2 reveal axonal dysfunction in various stages of multiple sclerosis and their inclusion to the biomarker panel may provide better insight into the extent of axonal damage/dysfunction.

Desferrioxamine in chronic progressive Multiple Sclerosis: a pilot study

1996 ◽  
Vol 2 (3) ◽  
pp. 157-160 ◽  
Author(s):  
Sharon G Lynch ◽  
Kathy Peters ◽  
Steven M LeVine
Keyword(s):  
Multiple Sclerosis ◽  
Pilot Study ◽  
Injection Site ◽  
Neurological Status ◽  
Progressive Multiple Sclerosis ◽  
Full Dose ◽  
Short Course ◽  
Chronic Progressive Multiple Sclerosis ◽  
The One ◽  
Multiple Sclerosis Patients

Chronic progressive Multiple Sclerosis is refractory to many conventional treatments. We performed a pilot study testing desferoxamine (DFO) as a candidate in the treatment of chronic progressive Multiple Sclerosis. DFO was given daily by 8 h subcutaneous infusions at a dose of 2 grams daily for 7 days, followed by 1 gram daily for 7 days. Eighteen of 19 individuals completed the full dose of 21 grams. One patient was unable to complete the course due to nausea. No acute deterioration of neurological status was seen during the administration of DFO. No worsening of vision or hearing was noted except that the one patient who was unable to tolerate the medication had a transient reduction in hearing. All patients had a local redness at the injection site. None of the patients had any sudden worsening during or shortly after the treatment This pilot study suggests that DFO is relatively well tolerated by Multiple Sclerosis patients when given in a short course of therapy.

Sign in / Sign up

Export Citation Format

Share Document